| Description | BTZ043 is a DprE1 inhibitor with nanomolar bactericidal activity against Mycobacterium tuberculosis in vitro. |
| In vitro | BTZ耐药DprE1的抑制遵循了MIC测量中观察到的趋势，其中C387 g突变体对PyrBTZ01、PyrBTZ02和BTZ043的抑制更为耐药，IC50增加了7到9倍，而C387S突变体的IC50增加了2.5到4倍。 |
| In vivo | BTZ-043按100 mg/kg（b.i.d., p.o.）剂量给药，作为阳性对照组，采用了含100 mg/kg 磺胺甲恶唑的复方制剂磺胺嘧啶/甲氧苄啶（SXT）。 |
| molecular weight | 431.39 |
| Molecular formula | C17H16F3N3O5S |
| CAS | 1161233-85-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 15 mg/mL (34.77 mM), Sonication is recommended. |
| References | 1. Makarov V, et al. Science, 2009, 324(5928), 801-804. 2. Lechartier B, et al. Antimicrob Agents Chemother, 2012. |